These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. gamma-Secretase as a therapeutic target in Alzheimer's disease. Guardia-Laguarta C; Pera M; Lleó A Curr Drug Targets; 2010 Apr; 11(4):506-17. PubMed ID: 20015011 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies. Evin G; Sernee MF; Masters CL CNS Drugs; 2006; 20(5):351-72. PubMed ID: 16696577 [TBL] [Abstract][Full Text] [Related]
6. [Alzheimer's disease treatment by inhibition/modulation of the gamma-secretase activity]. Tomita T Rinsho Shinkeigaku; 2009 Nov; 49(11):845-7. PubMed ID: 20030227 [TBL] [Abstract][Full Text] [Related]
7. Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation. Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A Curr Med Chem; 2011; 18(35):5430-47. PubMed ID: 22087836 [TBL] [Abstract][Full Text] [Related]
8. γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. Imbimbo BP; Giardina GA Curr Top Med Chem; 2011; 11(12):1555-70. PubMed ID: 21510832 [TBL] [Abstract][Full Text] [Related]
9. γ-Secretase as a target for Alzheimer's disease. Wolfe MS Adv Pharmacol; 2012; 64():127-53. PubMed ID: 22840746 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of gamma-secretase inhibitors and modulators. Imbimbo BP Curr Top Med Chem; 2008; 8(1):54-61. PubMed ID: 18220933 [TBL] [Abstract][Full Text] [Related]
11. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease. D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891 [TBL] [Abstract][Full Text] [Related]
12. Quantification of gamma-secretase modulation differentiates inhibitor compound selectivity between two substrates Notch and amyloid precursor protein. Yang T; Arslanova D; Gu Y; Augelli-Szafran C; Xia W Mol Brain; 2008 Nov; 1():15. PubMed ID: 18983676 [TBL] [Abstract][Full Text] [Related]
13. Development and mechanism of γ-secretase modulators for Alzheimer's disease. Crump CJ; Johnson DS; Li YM Biochemistry; 2013 May; 52(19):3197-216. PubMed ID: 23614767 [TBL] [Abstract][Full Text] [Related]
14. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883 [TBL] [Abstract][Full Text] [Related]
15. γ-secretase substrates and their implications for drug development in Alzheimer's disease. Lleó A; Saura CA Curr Top Med Chem; 2011; 11(12):1513-27. PubMed ID: 21510835 [TBL] [Abstract][Full Text] [Related]